Trials of gene therapy for pancreatic carcinoma

Halloran, Christopher; Ghaneh, Paula; Costello, Eithne; Neoptolemos, John P.

doi:10.1007/s11894-005-0028-7

Cited by 2 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many gene delivery methods have been explored for PC gene therapy. [4][5][6][7] We have experimented with nonviral vectors, adenoviral and SV40-based vectors, which showed gene delivery to PC cells, and provided evidence of therapeutic efficacy. [8][9][10][11] However, the current low transduction efficiency of the synthetic nonviral vector and the transient gene expression using both viral vectors present major disadvantages in the cost of clinical application.…”

Section: Introductionmentioning

confidence: 99%

Using lentiviral vectors for efficient pancreatic cancer gene therapy

et al. 2009

View full text Add to dashboard Cite

Pancreatic cancer (PC) remains a life-threatening disease. Efficient therapeutic gene delivery to PC-derived cells continues to present challenges. We used self-inactivated lentiviral vectors to transduce PC-derived cells in vitro and in vivo. We showed that lentiviral vectors transduce PC-derived cell lines with high efficiency (490%), regardless of the differentiation state of the cell. Next, we transferred human interferon beta (hIFN-b) gene. Expression of hIFN-b in PC cells using lentiviral vectors resulted in the inhibition of cell proliferation and the induction of cell death by apoptosis. In vivo, lentiviral administration of hIFN-b prevented PC tumor progression for up to 15 days following gene therapy, and induced tumor regression/stabilization in 50% of the mice treated. Again, hIFN-b expression resulted in cancer cell proliferation inhibition and apoptosis induction. We provide evidence that human immunodeficiency virus (HIV)-1-based lentiviral vectors are very efficient for gene transfer in PC-derived cells in vitro and in vivo. As a consequence, delivery of hIFN-b stopped PC tumor progression. Thus, our approach could be applied to the 85% of PC patients with a locally advanced disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Using lentiviral vectors for efficient pancreatic cancer gene therapy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…With respect to gene therapy approaches for pancreatic cancer, a variety of gene delivery methods as well as intracellular targets have been explored. [7][8][9] Our own experience has been with adenoviral vectors, which showed efficient gene delivery to pancreatic cancer cells. 10,11 However, for this vector type to be used in humans, barriers such as pre-existing immunity and shortlived expression need to be overcome.…”

Section: Introductionmentioning

confidence: 99%